8-KCorporate ChangesExhibits & Filings

BIOGEN INC. 8-K Report, Bylaw Amendment (Dec 12, 2023)

Filed December 12, 2023For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on December 12, 2023, detailing amendments to its Fifth Amended and Restated Bylaws, effective December 6, 2023. The primary focus of these amendments is to update procedural mechanics and disclosure requirements related to stockholder meetings, particularly concerning the submission of business proposals and director nominations. These changes aim to enhance transparency and streamline the proxy solicitation process. Key updates include more stringent disclosure requirements for stockholders proposing business, such as detailing derivative or synthetic arrangements that mirror long positions in company shares. Additionally, provisions related to director nominations have been enhanced to align with Rule 14a-19 of the Securities Exchange Act, requiring significant proxy solicitation efforts (at least 67% of voting power) and specific disclosures from nominating stockholders and their nominees. The amendments also clarify procedures for meeting adjournments, quorum establishment, and the revocability of proxies.

Key Highlights

  • 1Biogen updated its Fifth Amended and Restated Bylaws to enhance procedural mechanics and disclosure requirements for stockholder meetings.
  • 2Stricter disclosure rules are now in place for stockholders intending to present business proposals, requiring details on derivative or synthetic arrangements that mimic share ownership.
  • 3Bylaws now mandate that if a stockholder proposing business does not appear at the meeting, the company is not obligated to present it.
  • 4Amendments align director nomination and proxy solicitation rules with SEC Rule 14a-19, requiring significant solicitation efforts (67% voting power) and detailed disclosures.
  • 5The company has reserved the use of white proxy cards exclusively for the Board of Directors, requiring other soliciting parties to use different colored cards.
  • 6Enhanced background information and disclosures are now required for director nominees and the stockholders nominating them.
  • 7Updates include clarifications on adjournment procedures, stockholder lists, abstentions, broker non-votes, and proxy revocability.

Frequently Asked Questions

The main purpose of these amendments is to update and enhance the procedural mechanics and disclosure requirements related to stockholder meetings, particularly concerning the submission of business proposals and director nominations. This aims to improve transparency, streamline processes, and align with regulatory requirements like SEC Rule 14a-19.

Stockholders proposing business must now disclose any derivative or synthetic arrangement that has the characteristics of a long position in Biogen shares, or any transaction designed to produce economic benefits and risks substantially corresponding to share ownership. They must also acknowledge that if they or their representative do not appear at the meeting to present the business, the company is not required to bring it to a vote.

The amendments significantly enhance requirements for director nominations, aligning with SEC Rule 14a-19. This includes requiring nominating stockholders to represent intent to solicit proxies from at least 67% of voting power, provide evidence of such solicitation, notify the company of changes in intent, and provide extensive background information on nominees and the proposing stockholder. The company also reserves white proxy cards for its own use.

Yes, the amendments require any stockholder indirectly or directly soliciting proxies to use a proxy card color other than white, as white proxy cards are reserved for the Board's exclusive use. Additionally, proxies are now generally revocable at the stockholder's pleasure unless stated otherwise and permitted by law to be irrevocable.